India Pharmaceuticals Trade
India is the world's largest supplier of generic medicines by volume, accounting for roughly 20% of global generic drug exports. Often called the "pharmacy of the world," India manufactures and exports affordable medicines to over 200 countries, with the United States being the single largest market — absorbing around 30% of India's total pharma exports by value.
The sector is anchored by companies such as Sun Pharma, Dr. Reddy's, Cipla, Lupin, and Aurobindo. These firms have built extensive US FDA-approved manufacturing facilities and have developed deep regulatory expertise, making India's pharma export base unusually resilient compared to other industries.
One structural risk the sector faces is dependence on China for active pharmaceutical ingredients (APIs). Roughly 60-70% of India's API requirements come from China. This dependency became a major policy concern during COVID-19, and the government has since introduced a Production Linked Incentive (PLI) scheme specifically for API manufacturing to reduce this vulnerability.
| Year | Exports | YoY | Imports | YoY | Balance |
|---|---|---|---|---|---|
| FY 2025-26 | $10.3B | -58.0% | $1.4B | -53.9% | +$8.9B |
| FY 2024-25 | $24.6B | +11.2% | $3.0B | +15.3% | +$21.6B |
| FY 2023-24 | $22.1B | +11.3% | $2.6B | -1.2% | +$19.5B |
| FY 2022-23 | $19.9B | +2.4% | $2.6B | -24.0% | +$17.2B |
| FY 2021-22 | $19.4B | +0.1% | $3.4B | +34.8% | +$16.0B |
- →India supplies ~20% of global generic medicines by volume
- →USA is the top destination (30%+ of exports); followed by UK, South Africa, Brazil
- →PLI scheme incentivising domestic API production to cut China dependence
- →Biosimilars and complex generics are the next growth frontier
- →Generic drug price erosion in the US remains the key margin headwind
Pharma exports are a direct revenue driver for NSE-listed names like SUNPHARMA, DRREDDY, CIPLA, LUPIN, and AUROPHARMA. Rising export revenue, US FDA approvals, and new product launches in the US market are the key catalysts to track. Currency depreciation (weaker rupee vs USD) is a structural tailwind for exporters.